The Pharmacy That Could End Antibiotics

The antibiotic costs less than a cup of tea. No prescription needed. The pharmacist doesn't ask questions.

In a narrow lane in Mumbai, a mother hands over a few rupees and walks away with a course of amoxicillin for her feverish child. No doctor. No diagnosis. Just the fastest, cheapest medicine available. This scene plays out millions of times a day across India—and it may be quietly dismantling one of modern medicine's most important defenses.

Anthropologist Assa Doron and sociologist Alex Broom have called India the global accelerant of the antimicrobial resistance (AMR) crisis. It's a striking phrase. But the data behind it is harder to dismiss.

When Access Becomes a Double-Edged Sword

Antimicrobial resistance already kills. According to the World Health Organization, drug-resistant infections directly caused 1.27 million deaths in a single year and contributed to nearly 5 million more. That's more than HIV/AIDS and malaria combined. And the projections are worse: without intervention, AMR could claim 10 million lives annually by 2050.

India sits at the center of this crisis for two reasons that pull in opposite directions. It is simultaneously one of the world's largest consumers of antibiotics and its largest producer of generic medicines. Drugs are cheap, plentiful, and—despite laws technically requiring prescriptions—effectively available over the counter to anyone who asks.

The underlying driver isn't recklessness. It's desperation.

In rural India, seeing a doctor can mean half a day of travel and a cost that exceeds a daily wage. The local pharmacy is a five-minute walk. For hundreds of millions of people, self-medicating with antibiotics isn't irresponsible behavior—it's rational problem-solving within a broken system. The tragedy is that this rational behavior, multiplied across a population of 1.4 billion, creates conditions where bacteria evolve faster than medicine can respond.

Superbugs Don't Carry Passports

Here's why this matters to someone sitting in London, Seoul, or Chicago.

Sponsored

Advertise with Us

[email protected]

Sponsored

Resistant bacteria don't respect borders. They travel on planes, in food supply chains, in the bodies of returning travelers. The New Delhi Metallo-beta-lactamase (NDM-1) enzyme—which renders bacteria resistant to nearly all known antibiotics—was first identified in India and has since been detected in hospitals across Europe, North America, and East Asia. Cases have been reported in South Korean hospitals. Infections that were once routine to treat are becoming untreatable.

This is the structural similarity between AMR and climate change: the consequences are shared globally, but the conditions that create the problem are concentrated in specific places. And as with climate change, the communities least responsible for the crisis will likely suffer its worst effects first.

It's Complicated—And That's the Point

It would be easy—and wrong—to frame this as an India problem.

The overuse of antibiotics in Western industrial livestock farming has contributed enormously to resistance. The pharmaceutical industry's retreat from antibiotic R&D, because the profit margins don't justify the investment, has left the pipeline nearly dry. Rich countries that consume antibiotics in hospital settings without adequate stewardship programs are part of the same story. India is the most visible node in a global failure, not its sole author.

There's also a tension that resists easy resolution. India's generic pharmaceutical industry is the backbone of affordable medicine for much of the developing world. Stricter regulation of antibiotic sales—the obvious fix—could drive up prices and reduce access to drugs that millions of people genuinely need. The cure, applied carelessly, could create new harms.

Public health advocates argue for investment in healthcare infrastructure so that people have real alternatives to pharmacy self-treatment. Pharmaceutical researchers call for new economic models to incentivize antibiotic development. Policymakers debate whether global frameworks—like those emerging from the UN's AMR action plan—can actually be enforced across sovereign nations with vastly different healthcare systems.

None of these conversations are moving fast enough.

What Policymakers Are Getting Wrong

The dominant policy response to AMR has been to focus on stewardship: educating doctors and patients to use antibiotics more carefully. It's necessary. It's also insufficient.

Stewardship programs assume that people have access to proper diagnosis and treatment in the first place. They assume that patients can wait for a doctor's appointment rather than buying something at the pharmacy today. In contexts where those assumptions don't hold, stewardship messaging lands in a vacuum.

Doron and Broom argue that addressing AMR in places like India requires confronting the social and economic conditions that make antibiotic overuse rational—not just the behavior itself. That means health system investment, poverty reduction, and supply chain transparency. It means asking pharmaceutical companies to be accountable for how their products are distributed. It means wealthy nations accepting that their agricultural and industrial practices are part of the problem too.

This is a harder conversation than "take the full course of antibiotics."